Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Study of Radium-223 in Metastatic CRPC
NCT02346526Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2015
- Primary completion
- Oct 2019
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Massachusetts General Hospital. Primary endpoint: Bone Scan Index at 2 months. Started Apr 2015; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02346526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346526.